Trial Profile
A phase II single arm trial of single-agent vinflunine as second-line treatment of advanced non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 May 2012
Price :
$35
*
At a glance
- Drugs Vinflunine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 May 2012 Actual patient number is 70 as reported by ClinicalTrials.gov.
- 24 Jan 2008 The expected completion date for this trial is now 1 Mar 2008.